Cargando…

p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.

Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eig...

Descripción completa

Detalles Bibliográficos
Autores principales: Honda, K., Sbisà, E., Tullo, A., Papeo, P. A., Saccone, C., Poole, S., Pignatelli, M., Mitry, R. R., Ding, S., Isla, A., Davies, A., Habib, N. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149958/
https://www.ncbi.nlm.nih.gov/pubmed/9514057
_version_ 1782144558718517248
author Honda, K.
Sbisà, E.
Tullo, A.
Papeo, P. A.
Saccone, C.
Poole, S.
Pignatelli, M.
Mitry, R. R.
Ding, S.
Isla, A.
Davies, A.
Habib, N. A.
author_facet Honda, K.
Sbisà, E.
Tullo, A.
Papeo, P. A.
Saccone, C.
Poole, S.
Pignatelli, M.
Mitry, R. R.
Ding, S.
Isla, A.
Davies, A.
Habib, N. A.
author_sort Honda, K.
collection PubMed
description Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P= 0.003). IMAGES:
format Text
id pubmed-2149958
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21499582009-09-10 p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Honda, K. Sbisà, E. Tullo, A. Papeo, P. A. Saccone, C. Poole, S. Pignatelli, M. Mitry, R. R. Ding, S. Isla, A. Davies, A. Habib, N. A. Br J Cancer Research Article Forty-two patients with hepatocellular carcinoma (HCC) were resected and their tumours were analysed for p53 mutations by GC-clamped denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and gene sequencing. All the exons have been analysed in this study. Eight of 12 HCCs with cirrhosis due to viral hepatitis and the two patients with sarcomatoid changes displayed p53 mutations. In contrast, no mutation was observed in the fibrolamellar variant (n = 9), non-cirrhotics (n = 13) and alcoholic cirrhosis (n = 6). The mutations observed were in exons 5-8. Two mutations were observed in codons 136 and 213 as well as a T insertion between residues 156 and 157 (exon 5) and these are reported for the first time in HCC. Likewise, the silent mutation polymorphism in codon 213 was noticed in 3 of the 42 patients. Survival analysis of these patients after surgery showed the mean and median survival in patients with wild-type p53 to be 60 and 43 months respectively. In the group with p53 mutations, the mean and median survival was 15 and 12 months. The difference was statistically significant (P= 0.003). IMAGES: Nature Publishing Group 1998-03 /pmc/articles/PMC2149958/ /pubmed/9514057 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Honda, K.
Sbisà, E.
Tullo, A.
Papeo, P. A.
Saccone, C.
Poole, S.
Pignatelli, M.
Mitry, R. R.
Ding, S.
Isla, A.
Davies, A.
Habib, N. A.
p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title_full p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title_fullStr p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title_full_unstemmed p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title_short p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
title_sort p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149958/
https://www.ncbi.nlm.nih.gov/pubmed/9514057
work_keys_str_mv AT hondak p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT sbisae p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT tulloa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT papeopa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT sacconec p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT pooles p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT pignatellim p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT mitryrr p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT dings p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT islaa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT daviesa p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation
AT habibna p53mutationisapoorprognosticindicatorforsurvivalinpatientswithhepatocellularcarcinomaundergoingsurgicaltumourablation